Literature DB >> 21079099

Risk factors for invasive breast cancer when core needle biopsy shows ductal carcinoma in situ.

Emil D Kurniawan1, Allison Rose, Arlene Mou, Malcolm Buchanan, John P Collins, Matthew H Wong, Julie A Miller, G Bruce Mann.   

Abstract

HYPOTHESIS: A core needle biopsy (CNB) diagnosis of ductal carcinoma in situ (DCIS) may be associated with a final diagnosis of invasive cancer. Preoperative radiologic, clinical, and pathological features may identify patients at high risk of diagnostic upstaging, who may be appropriate candidates for sentinel node biopsy at initial surgery.
DESIGN: Review of prospectively collected database.
SETTING: Tertiary teaching referral hospital and a population-based breast screening center. PATIENTS: Consecutive patients from January 1, 1994, to December 31, 2006, whose CNB findings showed DCIS or DCIS with microinvasion. MAIN OUTCOME MEASURES: Upstaging to invasive cancer.
RESULTS: Eleven of 15 cases of DCIS with microinvasion (73.3%) and 65 of 375 cases of DCIS (17.3%) were upstaged to invasive cancer. Ten of 21 palpable lesions (47.6%) were found to have microinvasion. For impalpable DCIS, multivariate analysis showed that noncalcific mammographic features (mass, architectural distortion, or nonspecific density) (odds ratio [95% confidence interval], 2.00 [1.02-3.94]), mammographic size of 20 mm or greater (2.80 [1.46-5.38]), and prolonged screening interval of 3 years or longer (4.41 [1.60-12.13]) were associated with upstaging. The DCIS grade on CNB was significant on univariate analysis (P = .04). The rate of upstaging increased with the number of significant factors present in a patient: 8.3% in patients with no risk factors, 20.8% in those with 1 risk factor, 39.6% in those with 2 risk factors, and 57.1% in those with 3 risk factors.
CONCLUSIONS: The risk of upstaging can be estimated by using preoperative features in patients with DCIS on CNB. We propose a management algorithm that includes sentinel node biopsy for patients with DCIS who have microinvasion on CNB, palpable DCIS, 2 or more predictive factors, and planned total mastectomy.

Entities:  

Mesh:

Year:  2010        PMID: 21079099     DOI: 10.1001/archsurg.2010.243

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  13 in total

1.  Detection of invasive components in cases of breast ductal carcinoma in situ on biopsy by using apparent diffusion coefficient MR parameters.

Authors:  Naoko Mori; Hideki Ota; Shunji Mugikura; Chiaki Takasawa; Junya Tominaga; Takanori Ishida; Mika Watanabe; Kei Takase; Shoki Takahashi
Journal:  Eur Radiol       Date:  2013-06-04       Impact factor: 5.315

2.  Factors associated with upstaging of ductal carcinoma in situ diagnosed by core needle biopsy using imaging guidance.

Authors:  Cholatip Wiratkapun; Pachara Patanajareet; Bussanee Wibulpholprasert; Panuwat Lertsithichai
Journal:  Jpn J Radiol       Date:  2011-09-17       Impact factor: 2.374

3.  Can Occult Invasive Disease in Ductal Carcinoma In Situ Be Predicted Using Computer-extracted Mammographic Features?

Authors:  Bibo Shi; Lars J Grimm; Maciej A Mazurowski; Jay A Baker; Jeffrey R Marks; Lorraine M King; Carlo C Maley; E Shelley Hwang; Joseph Y Lo
Journal:  Acad Radiol       Date:  2017-05-11       Impact factor: 3.173

4.  Prediction of invasive breast cancer using shear-wave elastography in patients with biopsy-confirmed ductal carcinoma in situ.

Authors:  Jae Seok Bae; Jung Min Chang; Su Hyun Lee; Sung Ui Shin; Woo Kyung Moon
Journal:  Eur Radiol       Date:  2016-04-16       Impact factor: 5.315

5.  Sentinel lymph node biopsy in patients with breast ductal carcinoma in situ: Chinese experiences.

Authors:  Xiao Sun; Hao Li; Yan-Bing Liu; Zheng-Bo Zhou; Peng Chen; Tong Zhao; Chun-Jian Wang; Zhao-Peng Zhang; Peng-Fei Qiu; Yong-Sheng Wang
Journal:  Oncol Lett       Date:  2015-07-10       Impact factor: 2.967

6.  Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast.

Authors:  Michael J Campbell; Frederick Baehner; Tess O'Meara; Ekene Ojukwu; Booyeon Han; Rita Mukhtar; Vickram Tandon; Max Endicott; Zelos Zhu; Jasmine Wong; Gregor Krings; Alfred Au; Joe W Gray; Laura Esserman
Journal:  Breast Cancer Res Treat       Date:  2016-10-26       Impact factor: 4.872

7.  Factors Associated With Underestimation of Invasive Cancer in Patients With Ductal Carcinoma In Situ: Precautions for Active Surveillance.

Authors:  Carlos Chavez de Paz Villanueva; Valentina Bonev; Maheswari Senthil; Naveenraj Solomon; Mark E Reeves; Carlos A Garberoglio; Jukes P Namm; Sharon S Lum
Journal:  JAMA Surg       Date:  2017-11-01       Impact factor: 14.766

8.  Prediction of Upstaging in Ductal Carcinoma in Situ Based on Mammographic Radiomic Features.

Authors:  Rui Hou; Lars J Grimm; Maciej A Mazurowski; Jeffrey R Marks; Lorraine M King; Carlo C Maley; Thomas Lynch; Marja van Oirsouw; Keith Rogers; Nicholas Stone; Matthew Wallis; Jonas Teuwen; Jelle Wesseling; E Shelley Hwang; Joseph Y Lo
Journal:  Radiology       Date:  2022-01-04       Impact factor: 29.146

9.  Prediction of Occult Invasive Disease in Ductal Carcinoma in Situ Using Deep Learning Features.

Authors:  Bibo Shi; Lars J Grimm; Maciej A Mazurowski; Jay A Baker; Jeffrey R Marks; Lorraine M King; Carlo C Maley; E Shelley Hwang; Joseph Y Lo
Journal:  J Am Coll Radiol       Date:  2018-02-02       Impact factor: 5.532

10.  Ductal carcinoma in situ of the breast.

Authors:  Richard J Lee; Laura A Vallow; Sarah A McLaughlin; Katherine S Tzou; Stephanie L Hines; Jennifer L Peterson
Journal:  Int J Surg Oncol       Date:  2012-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.